Open AccessTreatment options in pulmonary arterial hypertension
Author(s) -
Toshner Mark
Publication year - 2007
Publication title -
future prescriber
Language(s) - English
Resource type - Journals
eISSN - 1931-2261
pISSN - 1468-9871
DOI - 10.1002/fps.29
Subject(s) - medicine , thickening , pulmonary hypertension , cardiology , life expectancy , heart failure , population , chemistry , environmental health , polymer science
Pulmonary arterial hypertension (PAH) is a rare, severe and progressive disease characterised by raised pressures in the arteries in the lungs leading to right heart failure and, historically, a median life expectancy of 2.8 years with‐out targeted treatment. 1 Pathologically, it is characterised by a thickening of the muscular layer of the arteries, dysfunction of the vessel walls, and abnormal growth of supporting cells such as fibroblasts. Copyright © 2007 Wiley Interface Ltd
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom